ENTRESTO 200 MG (97/103 MG) 56 F.C.TABS

Heart Failure Indicated to reduce the risk of cardiovascular death and hospitalization for heart failure (HF) in patients with chronic heart failure (CHF) (NYHA class II-IV) and reduced ejection fraction. Recommended starting dose: 49 mg/51 mg PO BID Target maintenance dose: After 2-4 weeks double the dose to the target maintenance dose of 97 mg/103 mg PO BID as tolerated